Company: BLTE
Filing Date: 2025-12-02
Form Type: 424B5
Source: 0001104659-25-117702
Chunk: 18

Company: BELITE BIO, INC
Filing Date: 2025-12-02
Form: 424B5
Chunk 18
---
vested restricted share units under the Company’s 2022 Performance Incentive Plan; and

•

3,103,470 ordinary shares (including ordinary shares represented by ADSs) to be issued upon the exercise of warrants outstanding.

Unless otherwise indicated, all information contained in this prospectus supplement assumes no exercise or termination of the outstanding options and warrants described above, no vesting and settlement or termination of the restricted share units described above and no issuance of additional equity awards under the equity incentive plans described above.

<div align='center'>S-11</div>

TABLE OF CONTENTS

### RISK FACTORS
Investing in the ADSs involves a high degree of risk. You should carefully review the risks and uncertainties described below and under the section titled “Risk Factors” in our most recent Annual Report on Form 20-F and any subsequent reports on Form 6-K we file after the date of this prospectus supplement, and all other information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus, as updated by our subsequent filings under the Exchange Act, before acquiring any ADSs. The occurrence of any of these risks might cause you to lose all or part of your investment in the ADSs.

**Risks Related to the Discovery, Development and Commercialization of Our Product Candidates**

Our product candidates are subject to extensive regulation. However, we have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.

The process of obtaining regulatory approvals in the United States, the PRC, the EU and other jurisdictions is expensive, may take many years if additional clinical trials are required and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in or the enactment of additional laws, regulations or approval policies may cause delays in the approval process or rejection of an application.

We have never obtained marketing approval for a product candidate. It is possible that the FDA, the TGA, the NMPA, the EMA or other comparable regulatory authority may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA, the TGA, the NMPA, the EMA or other comparable regulatory authority does not accept or approve our NDAs for any of our product candidates, it may require that we conduct additional clinical trials,